Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Prepaid Assets (2020 - 2026)

InMed Pharmaceuticals has reported Prepaid Assets over the past 5 years, most recently at $660280.0 for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 2.53% year-over-year to $660280.0; the TTM value through Dec 2025 reached $660280.0, up 2.53%, while the annual FY2025 figure was $321747.0, 32.65% down from the prior year.
  • Prepaid Assets for Q4 2025 was $660280.0 at InMed Pharmaceuticals, up from $191755.0 in the prior quarter.
  • Over five years, Prepaid Assets peaked at $1.3 million in Q1 2022 and troughed at $140512.0 in Q4 2021.
  • A 5-year average of $589693.2 and a median of $507872.0 in 2025 define the central range for Prepaid Assets.
  • Biggest five-year swings in Prepaid Assets: surged 488.51% in 2022 and later tumbled 50.14% in 2025.
  • Year by year, Prepaid Assets stood at $140512.0 in 2021, then surged by 488.51% to $826931.0 in 2022, then skyrocketed by 34.59% to $1.1 million in 2023, then plummeted by 42.14% to $643986.0 in 2024, then rose by 2.53% to $660280.0 in 2025.
  • Business Quant data shows Prepaid Assets for INM at $660280.0 in Q4 2025, $191755.0 in Q3 2025, and $321747.0 in Q2 2025.